Bristol-Myers Squibb Company (BMY) Thursday released the interim results from a Phase II open-label study of daclatasvir and GS-7977, a nucleotide NS5B polymerase inhibitor, used in treatment of patients with hepatitis C genotypes 1, 2 and 3.
The company stated that the analysis of a combination of the two oral, once-daily investigational compounds taken for 24 weeks, with or without ribavirin, achieved a rapid and sustained viral response.
The company further stated that 100% of patients with genotype 1, 2, or 3 HCV achieved viral load below the lower limit of quantification at Week 4 on treatment.
Mark Sulkowski, MD, Professor of Medicine, Medical Director, Viral Hepatitis Center, Johns Hopkins University School of Medicine, said:. "The interim results of this study indicate that combining the potent antiviral activity of daclatasvir with a nucleotide analogue polymerase inhibitor has the potential to address this goal for the treatment of HCV genotypes 1, 2 and 3, and warrants further study to more fully evaluate this combination."
For comments and feedback contact: editorial@rttnews.com
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.